Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ING Groep NV — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.41 (market cap $5.07B), while ING Groep NV trades at $35.59 (market cap $101.22B). The key difference: ING Groep NV is far larger — about 20× ACADIA Pharmaceuticals Inc.'s market cap, and ING Groep NV pays a 3.73% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ING | |
|---|---|---|
Market Cap | $5.07B | $101.22B |
Sector | Health | Financials |
52-Week High | $29.41 | $35.92 |
52-Week Low | $20.06 | $23.66 |
Enterprise Value | $4.19B | — |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
ING trades at $35.24, down 1.23% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.79, and raised its full-year revenue guidance. Analyst consensus is strongly positive with 62.5% buy ratings. Recent news highlights strategic acquisitions and a dividend payment scheduled for August 2026.
The outlook for ING is favorable, supported by earnings momentum and upward guidance revisions. Key opportunities include growth in net interest income and fee-based revenue. Risks involve persistent negative operating cash flows and sensitivity to European economic conditions. The stock presents a value proposition with a P/E of 13.24, though cash flow trends warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
